CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medic…
Category: Business
Tenpoint Therapeutics Announces United Kingdom YUVEZZI™ Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults
LONDON & WARREN, N.J.–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced the submission of a Marketing…
Sydnexis Announces FDA Advisory Committee Meeting to Review NDA for SYD-101 for Pediatric Progressive Myopia
DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis Announces FDA Advisory Committee Meeting to Review NDA for SYD-101 for Pediatric Progressive Myopia
AM Best Withdraws Credit Ratings of Vision Service Plan and Its Subsidiaries
OLDWICK, N.J.–(BUSINESS WIRE)–AM Best has affirmed the Financial Strength Rating (FSR) of A- (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a-” (Excellent) of Vision Service Plan (Rancho Cordova, CA) and its subsidiaries, col…
Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care
VAUGHAN, Ontario, & MENLO PARK, Calif.–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the creation of Orphia™, a new AI-powered di…
GenSight Biologics publie sa situation de trésorerie au 30 juin 2026 et fait un point sur son activité
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurod…
GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Bifrost Biosystems Pens Agreement with Illumina for Supply of Sequencing Chemistry for Optical Pooled Screening Platform
BERKELEY, Calif.–(BUSINESS WIRE)– #AIDrugDiscovery–Bifrost Biosystems today announced that it has secured a commercial supply agreement with Illumina enabling integration of Illumina’s industry-standard sequencing-by-synthesis (SBS) chemistry into i…
FGX International and True Religion Announce New Licensing Agreement for Eyewear Collection
SMITHFIELD, R.I.–(BUSINESS WIRE)–FGX International, an EssilorLuxottica company and one of the world’s leading over-the-counter eyewear brands, has announced a new licensing agreement with the iconic global lifestyle brand, True Religion. Under the a…
ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical
SALT LAKE CITY–(BUSINESS WIRE)–ClearOne, Inc. (Nasdaq: CLRO) (“ClearOne”) announced today that it has entered into a definitive agreement and plan of merger (the “Agreement”) among its wholly-owned subsidiary (“MergerSub”), Vivani Medical, Inc. (Nasd…
Azalea Vision si aggiudica il prestigioso finanziamento dell'Acceleratore EIC che porta le sue lenti a contatto intelligenti verso la fase dello sviluppo clinico
GAND, Belgio–(BUSINESS WIRE)–Azalea Vision, healthtech belga impegnata nello sviluppo della prima lente a contatto intelligente di grado medico, oggi ha reso noto di essere stata selezionata nell’ambito dell’Acceleratore del Consiglio europeo per l’i…
Prestigieuze EIC Accelerator-financiering verleend aan Azalea Vision voor de klinische ontwikkeling van slimme contactlenzen
GENT, België–(BUSINESS WIRE)–Azalea Vision, een Belgisch bedrijf op het gebied van gezondheidstechnologie dat de eerste medische slimme contactlenzen produceert, kondigde vandaag aan dat het werd geselecteerd voor de European Innovation Council (EIC)…
Azalea Vision obtiene la prestigiosa financiación del EIC Accelerator para impulsar el desarrollo clínico de su lente de contacto inteligente
GANTE, Bélgica–(BUSINESS WIRE)–Azalea Vision, empresa belga de tecnología sanitaria que desarrolla la primera lente de contacto inteligente de uso médico, ha anunciado hoy su selección para recibir financiación del EIC Accelerator, el programa insign…
アザレア・ビジョン、スマート・コンタクト・レンズを臨床開発段階へ進めるため、権威あるEICアクセラレータの資金提供を獲得
ベルギー・ゲント–(BUSINESS WIRE)–（ビジネスワイヤ） — ベルギーのヘルステック企業であるアザレア・ビジョンは、初の医療グレードのスマート・コンタクト・レンズを開発しており、欧州イノベーション会議（EIC）のアクセラレータに採択されたと発表しました。これは、新市場を創出する画期的なディープテックを対象とする欧州連合（EU）の主力プログラムです。同社は今回のラウンドでベルギーから唯一採択された企業であり、医療グレードのスマート・コンタクト・レンズ・プラットフォームを臨床開発へ進め…
Azalea Vision se voit attribuer le prestigieux financement de l'EIC Accelerator pour faire passer ses lentilles de contact intelligentes au stade du développement clinique
GHENT, Belgique–(BUSINESS WIRE)–Azalea Vision, une entreprise belge spécialisée dans les technologies de la santé qui développe la première lentille de contact intelligente de qualité médicale, a annoncé aujourd’hui avoir été sélectionnée pour partic…
Azalea Vision獲久負盛名的歐洲創新委員會（EIC）加速器資助，推進智慧隱形眼鏡的臨床開發
比利時根特–(BUSINESS WIRE)–(美國商業資訊)– 致力於開發首款醫用級智慧隱形眼鏡的比利時健康科技公司Azalea Vision今日宣布，獲選加入歐洲創新委員會（EIC）加速器計畫。歐盟的這一旗艦計畫旨在扶持能開創全新市場的突破性深度科技。Azalea是這次唯一獲選的比利時公司，將獲得最高750萬歐元資助，包括250萬歐元非稀釋性撥款，以及計劃中的500萬歐元EIC基金股權投資，以推進其醫療級智慧隱形眼鏡平台進入臨床開發階段。 除資金外，此次入選亦是對Azalea技術及長遠願景的…
Azalea Vision erhält die renommierte EIC Accelerator-Förderung zur Weiterentwicklung intelligenter Kontaktlinsen bis in die klinische Entwicklungsphase
GENT, Belgien–(BUSINESS WIRE)–Azalea Vision, ein belgisches Healthtech-Unternehmen, das die erste intelligente Kontaktlinse in medizinischer Qualität entwickelt, gab heute bekannt, dass es für den European Innovation Council (EIC) Accelerator ausgewä…
Hengrui Pharma的创新型环孢素滴眼液恒宜®在中国获批用于治疗干眼症
上海、德国海德堡和马萨诸塞州剑桥–(BUSINESS WIRE)–(美国商业资讯)– 专注于科技创新的全球性制药企业Hengrui Pharma与专注于研发基于其独特EyeSol®无水平台技术的同类首创及同类最佳眼科疗法的生物制药公司Novaliq GmbH (“Novaliq”)今日宣布，2026年6月23日，中国国家药品监督管理局(NMPA)已批准恒宜®（0.1%环孢素滴眼液）用于治疗干眼症患者，旨在增加泪液分泌减少患者的泪液分泌量，并改善疾病体征。 恒宜®是中国首个且目前唯一的无水0.1…
Hengruis Heng Yi® in China als innovative Cyclosporin-Augentropfen zur Behandlung des trockenen Auges zugelassen
SHANGHAI & HEIDELBERG, Deutschland & CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Hengrui Pharma, ein weltweit tätiges Pharmaunternehmen mit Schwerpunkt auf wissenschaftlicher und technologischer Innovation, und die Novaliq GmbH („Novaliq“), ein biopharm…
Samenvatting: Heng Yi® van Hengrui in China goedgekeurd als innovatieve oftalmische cyclosporine-oplossing voor de behandeling van het droge-ogen-syndroom
SHANGHAI & HEIDELBERG, Duitsland & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Hengrui Pharma, een wereldwijd farmaceutisch bedrijf dat zich richt op wetenschappelijke en technologische innovatie, en Novaliq GmbH (“Novaliq”), een biofarmaceutisch bedrijf dat zi…